Please assess the completion status of the following clinical trial:

Trial Title: Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients 18-74 years of age~* Single primary liver transplant from a deceased donor~* CellCept plus tacrolimus or cyclosporine from time of transplantation (within 72 hours)~* Patients with hepatitis C-positive status may be entered if they have had an intraoperative (back table) biopsy of the transplanted liver or will have a biopsy at the time of randomization. This is not required for patients negative for hepatitis C.~Exclusion Criteria:~* Liver allograft from a living donor or a split liver~* Multiple organ transplant~* Dialysis therapy for \>14 days from transplantation to randomization~* History of malignancy in the last 5 years (except hepatoma or non-melanoma skin cancer)~* Previous sirolimus therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- CellCept + CNI (tacrolimus or cyclosporine) (Type: EXPERIMENTAL): None
- CellCept + sirolimus (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).